Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest.
The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada.
All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery.
Most patients had their kidney completely removed.
This type of cancer returns in about a fifth of people, usually within one to two years.
Patients are monitored with CT scans, with their frequency based on the level of individual risk.
For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months.
These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score.
After 18 months, cancer had returned in 15% of the group.
The study found the urine test correctly detected recurrence in 90% of these patients.
It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free.
Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not.
'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit.
'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required.
'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.'
The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology.
Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
7 hours ago
- The Guardian
UnitedHealth faces federal scrutiny into whistleblower claims
US lawmakers on both sides of the aisle are raising concerns and seeking investigations in the wake of Guardian reporting on whistleblower claims about practices within UnitedHealth Group's nursing home partnership programs. One US senator has announced he is launching an investigation and two US representatives are now calling on the US Department of Justice to expand its reported investigations of the nation's largest healthcare conglomerate. Others said they are troubled by whistleblower allegations reported by the Guardian – including claims that UnitedHealth paid bonuses to nursing homes to help reduce residents' hospital transfers and used improper sales tactics to get nursing home residents to sign up for the company's Medicare Advantage plans. Two Democratic members of Congress – representatives Alexandria Ocasio-Cortez of New York and Lloyd Doggett of Texas – filed a letter on Monday that urges the Department of Justice to 'thoroughly review new revelations from investigative reporting and whistleblower complaints, which suggest that UnitedHealth may have engaged in illegal activities'. 'The Guardian's findings reveal the need for a wide-ranging investigation by the Department of Justice into years, if not decades, of potential waste, fraud, and abuse at UnitedHealth,' the letter read. The lawmakers are demanding a briefing on current and planned investigations by 14 July. UnitedHealth vigorously denies the whistleblowers' allegations and says the Guardian's reporting on these issues is 'blatantly false and misleading'. In response to a question about the two representatives' letter, the company said the Department of Justice 'has already declined to pursue the matter' – a reference to the agency's previous decisions not to intervene in two whistleblower lawsuits against UnitedHealth filed under the US False Claims Act. One of those lawsuits was ultimately dropped and the other is pending in federal court in Georgia. Another Democrat, the Oregon senator Ron Wyden, announced last month on X that his office was 'launching a full investigation to verify these whistleblower accounts'. 'This reporting demands further inquiry – nobody deserves to have their medical care jeopardized to pad insurance company profits,' Wyden, the ranking member of the Senate's finance committee, said. 'My staff on the Finance Committee have a decade-long record of thorough and objective investigations that follow the facts towards solutions that improve federal health care policy for all Americans.' Senator Josh Hawley, a Missouri Republican who sits on the Senate investigations subcommittee, said it is 'alarming to hear these serious allegations' about the company's practices. 'I look forward to securing justice for patients, policyholders and whistleblowers alike who've been harmed by insurance companies.' Another Republican, Georgia representative Buddy Carter, expressed similar concerns. 'If these allegations are true, UnitedHealth must be held responsible for their gross abuse of patients,' Carter, chair of the House subcommittee on health, said in a statement. 'Patients should always come before profits.' Senator Richard Blumenthal of Connecticut, ranking member of the Senate investigations subcommittee, said the 'courage and conviction' of the whistleblowers will serve as 'an impetus for reform. Shining a light on abuses of consumer trust is a call to action – and a demand for accountability.' UnitedHealth says its partnerships with nursing homes ensure better care for seniors 'through on-site clinical care, personalized treatment plans, and enhanced coordination among caregivers'. The company says these arrangements have been highly successful in helping nursing homes prevent unnecessary hospital stays that can lead to serious issues such as delirium, falls, pressure injuries and 'sometimes even fatal consequences'. Two whistleblowers who worked for UnitedHealth as nurse practitioners submitted sworn declarations in May alleging that the company had used improper tactics to reduce hospital transfers for ailing nursing home residents. Their declarations were submitted to the Securities and Exchange Commission (SEC), the Federal Trade Commission (FTC), the Washington state attorney general's office and Congress, according to Whistleblower Aid, the non-profit assisting both nurse practitioners. Whistleblower Maxwell Ollivant's declaration, first reported on by the Guardian in May, says he witnessed UnitedHealth 'delay and deny medically necessary emergency care' to vulnerable nursing home residents in order to 'retain more money' from the payments that the company was receiving from the US government's Medicare Advantage program. Under Medicare Advantage, a private alternative to traditional Medicare, the federal government pays insurers a fixed sum to cover seniors' medical services. The less insurers spend on covering medical expenses, the more in public dollars they have left over. Ollivant's declaration alleges that UnitedHealth 'actively avoided medically necessary hospitalizations – hospitalizations in serious life-threatening situations, or situations to avoid imminent death or incredibly catastrophic results – to keep their costs down, and drove vulnerable patients toward signing Do Not Resuscitate (DNRs) and Do Not Hospitalize orders to avoid providing hospital services for life threatening illnesses'. UnitedHealth noted that the Department of Justice declined to join the lawsuit that Ollivant filed against the company and later dropped. The company said Ollivant 'is not in a position to assess the effectiveness of our programs – he lacks both the necessary data and the expertise'. The second whistleblower, whose declaration was filed anonymously, worked with UnitedHealth for several years. Her declaration says her experiences as a nurse practitioner within its nursing home programs gave her 'first-hand insight into the evolution and impact of substandard care practices resulting from the training, culture, processes and bonus system of delays and denials of medically necessary care'. That declaration criticizes the company's '[a]ggressive [p]ush for DNRs' and says 'the decision to receive life-saving care should rest with the patient or their legal representative, not myself, and certainly not the insurance company'. UnitedHealth said the allegations in the anonymous whistleblower's declaration show she 'did not fully understand our clinical model' and that her perspective 'does not reflect the dedication and excellence of the many outstanding clinicians who understand the impact they have in supporting their patients and improving health outcomes'. The company also denies the claims regarding DNRs. 'At no time have we encouraged or pushed' nursing home residents 'to sign a DNR directive', a UnitedHealth representative said. 'Our health care providers are ethically bound to respect patient autonomy and support informed decision-making without coercion.' The Guardian's previous reporting also references allegations relating to the legal claims of a third whistleblower, Brook Gonite, a former salesperson for UnitedHealth's nursing home program. Gonite alleges in a lawsuit in federal court in Georgia that UnitedHealth wrongly solicited and enrolled vulnerable, elderly patients for its nursing home programs through improper marketing tactics, including violations of Hipaa, the federal medical privacy act, and paid kickbacks to nursing homes to obtain illegal referrals of their residents. UnitedHealth denied those allegations and moved to dismiss Gonite's lawsuit. The Department of Justice, which declined to formally intervene in the case, opposed UnitedHealth's motion to dismiss. In April, federal judge Marc Treadwell denied UnitedHealth's motion to dismiss, finding that Gonite's lawsuit puts forth 'substantial and concerning' factual allegations that 'plausibly' assert violations of federal protections meant to ensure vulnerable nursing home residents can make informed decisions about their medical care. The company continues to deny those claims and says Gonite was fired for engaging in illegal sales tactics similar to those alleged in his suit. In a statement, the company said its employees 'are trained on compliant interactions with nursing home staff and nursing home residents, in accordance with the Medicare Marketing Guidelines and other applicable laws'. Last week, shortly before the Guardian was to publish a second story providing additional detail about Gonite's pending lawsuit and the other two whistleblowers' declarations, UnitedHealth filed a lawsuit against the Guardian in Delaware state court, claiming the allegations were false and libelous. In a statement, the company said 'the article published by The Guardian is not only riddled with inaccuracies – it is so blatantly false and misleading that we have filed a defamation lawsuit to hold the publication accountable and bring the full truth to light'. The Guardian has said it stands by its 'deeply sourced, independent reporting, which is based on thousands of corporate and patient records, publicly filed lawsuits, declarations submitted to federal and state agencies, and interviews with more than 20 current and former UnitedHealth employees – as well as statements and information provided by UnitedHealth itself over several weeks'.
Daily Mirror
5 days ago
- Daily Mirror
Japanese rover smashes into moon in fresh disaster for embattled space company
Japanese company ispace has declared a second failure in a bid for its lunar lander to touchdown on the moon after communication was lost less than two minutes before the scheduled grounding A lunar lander from a Japanese company crashed while attempting a touchdown on the moon in the latest casualty in the commercial rush to the moon and the second failure for the same company. The Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to gain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the moon with a mini rover. Until then, the descent from lunar orbit seemed to be going well. CEO and founder Takeshi Hakamada apologized to everyone who contributed to the mission, the second lunar strikeout for ispace. Two years ago, the company's first moonshot ended in a crash landing, giving rise to the name 'Resilience' for its successor lander. Resilience carried a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house for placement on the moon's dusty surface. Company officials said it was too soon to know whether the same problem doomed both missions. This is the second time that we were not able to land. So we really have to take it very seriously,' Hakamada told reporters. He stressed that the company would press ahead with more lunar missions. A preliminary analysis indicates the laser system for measuring the altitude did not work as planned, and the lander descended too fast, officials said. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' the company said in a written statement. Moon missions had previously been the preserve of governments but it became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another US company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience was targeting the top of the moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Plans had called for the 7.5-feet Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 5kgs, was going to stick close to the lander, going in circles at a speed of less than two centimetres per second. It was capable of venturing up to two-thirds of a mile from the lander and should be operational throughout the two-week mission, the period of daylight. Besides science and tech experiments, there was an artistic touch. The rover held a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Minutes before the attempted landing, Hakamada assured everyone that ispace had learned from its first failed mission. 'Engineers did everything they possibly could' to ensure success this time, he said. He considered the latest moonshot 'merely a steppingstone' to its bigger lander launching by 2027 with NASA involvement. Ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures, Jeremy Fix, chief engineer for ispace's US subsidiary, said at a conference last month. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded £74million. Two other US companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the US, China, India and Japan. Of those, only the US has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.
North Wales Chronicle
5 days ago
- North Wales Chronicle
Japanese lunar lander crashes while attempting touchdown on the Moon
Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to gain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the Moon with a mini rover. Until then, the descent from lunar orbit seemed to be going well. Takeshi Hakamada, ispace chief executive officer and founder, apologised to everyone who contributed to the mission, the second lunar strikeout for the company. Two years ago, the company's first moonshot ended in a crash landing, giving rise to the name Resilience for its successor lander. Resilience carried a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house for placement on the Moon's dusty surface. Company officials said it was too soon to know whether the same problem doomed both missions. 'This is the second time that we were not able to land. So we really have to take it very seriously,' Mr Hakamada told reporters. He stressed the company would press ahead with more lunar missions. A preliminary analysis indicates the laser system for measuring the altitude did not work as planned and the lander descended too fast, officials said. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' the company said in a written statement. Long the province of governments, the Moon became a target of private outfits in 2019, with more flops than successes along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the Moon faster and became the first private entity to successfully land there in March. Another US company, Intuitive Machines, arrived at the Moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the south pole and was declared dead within hours. Resilience was targeting the top of the Moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Plans had called for the 7.5ft Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for Nasa. The rover was going to stick close to the lander, going in circles at a speed of less than one inch per second.
